Panacea Biotec · NSE: PANACEABIO · BSE: 531349

Q1 FY21 results · Apr–Jun 2020

Panacea Biotec reported revenue from operations of ₹132.76 crore (up 5.5% from Q1 FY20) and net loss of ₹34.13 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	132.76	125.78	+5.5%	125.36	+5.9%
Other income	1.19	5.03	−76.3%	17.98	−93.4%
Total income	133.95	130.81	+2.4%	143.34	−6.6%
Profit before share of associates & JVs and tax	(32.83)	(23.75)	Loss widened	(59.40)	Loss narrowed
Share of profit/(loss) of associates & JVs	0.06	0.07		0.16
Net profit for the period	(34.13)	(28.27)	Loss widened	(69.70)	Loss narrowed
EPS, basic (₹)	(5.58)	(4.62)	Loss widened	(11.38)	Loss narrowed
Net margin (%)	-25.7	-22.5		-55.6

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY21	Q1 FY20	YoY	Q4 FY20	QoQ
Revenue from operations	76.48	24.82	+208.1%	56.77	+34.7%
Other income	2.87	1.14	+151.8%	27.80	−89.7%
Total income	79.35	25.96	+205.7%	84.57	−6.2%
Profit before tax	(8.10)	(18.81)	Loss narrowed	(6.62)	Loss widened
Net profit for the period	(8.84)	(29.21)	Loss narrowed	(32.48)	Loss narrowed
EPS, basic (₹)	(1.45)	(4.77)	Loss narrowed	(5.31)	Loss narrowed
Net margin (%)	-11.6	-117.7		-57.2

Consolidated

Filed with BSE: 04 Sep 2020, 16:36 IST
Board meeting: 03 Sep 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 04 Sep 2020, 16:36 IST
Board meeting: 03 Sep 2020
Period: 01 Apr 2020 to 30 Jun 2020
Review status: Unaudited
Source: XBRL filing on BSE